Fluoroquinolone resistance among gram-negative urinary tract patho-gens: Global smart program results, 2009-2010

Open Microbiology Journal

Volumn 6, Issue 1, 2012, Pages 74-78

  Bouchillon, Sam ^a   Hoban, Daryl J ^a   Badal, Robert ^a   Hawser, Stephen ^b  

^a Division of Microbiology   (United States)

^b International Health Management Associates Europe Sàrl   (Switzerland)

Author keywords

Ertapenem; Fluoroquinolone resistance; Imipenem; Smart global surveillance; Urinary tract infection

Indexed keywords

AMIKACIN; CARBAPENEM DERIVATIVE; CEFOTAXIME; CEFTAZIDIME; CLAVULANIC ACID; ERTAPENEM; EXTENDED SPECTRUM BETA LACTAMASE; IMIPENEM; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; BACTERIUM ISOLATION; CONTROLLED STUDY; ESCHERICHIA COLI; GEOGRAPHIC DISTRIBUTION; GRAM NEGATIVE BACTERIUM; HOSPITAL PATIENT; HUMAN; KLEBSIELLA PNEUMONIAE; MEDICAL RESEARCH; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; PROTEUS MIRABILIS; PSEUDOMONAS AERUGINOSA; TREND STUDY; URINARY TRACT INFECTION;

BACILLI (CLASS); NEGIBACTERIA;

EID: 84866469331     PISSN: None     EISSN: 18742858     Source Type: Journal    
DOI: 10.2174/1874285801206010074     Document Type: Article

References (14)

1. Aypak C, Altunsoy A, Duzgun N. Empiric antibiotic therapy in acute uncomplicated urinary tract infections and fluoroquinolone resistance: a prospective observational study. Ann Clin Microbiol Antimicrob 2009;8: 27.
2. Shigemura K, Arakawa S, Miura T, Nakano Y, Tanaka K, Fujisawa M. Significance of fluoroquinolone-resistant Escherichia coli in urinary tract infections. Jpn J Infect Dis 2008; 61: 226-8.
3. van der Mee-Marquet N, Savoyen P, Domelier-Valentin AS, Mourens C, Quentin R. CTX-M-type fluoroquinolone-resistant Es-cherichia coli: analysis of the colonization of residents and inani-mate surfaces 1 year after a first case of urinary tract infection a nursing home in France. Infect Control Hosp Epidemiol 2010;31: 968-70.
4. van der Starre WE, van Nieuwkoop C, Paltansing S, et al. Risk factors for fluoroquinolone-resistant Escherichia coli in adults with community-onset febrile urinary tract infection. J Antimicrob Chemother 2011;66(3): 650-6.
5. Rattanaumpawan P, Tolomeo P, Bilker WB, Fishman NO, Lauten-bach E. Risk factors for fluoroquinolone resistance in Gram-negative bacilli causing healthcare-acquired urinary tract infec-tions. J Hosp Infect 2010;76: 324-7.
6. Urban C, Mariano N, Bradford P A, et al. Identification of CTX-M ß-lactamases in Escherichia coli from hospitalized patients and res-idents of long-term care facilities. Diagn Microbiol Infect Dis 2010; 66: 402-6.
7. Lewis JS, Herrera M, Wickes B, Patterson JE, Jorgensen JH. First report of emergence of CTX-M-type extended-spectrum ß-lactamases (ESBLs) as the predominant ESBL isolated in a U.S. health care system. Antimicrob Agents Chemother 2007; 51: 4015-21.
8. Castanheira M, Mendes RE, Rhomberg PR, Jones RN. Rapid emergence of blaCTX-M among Enterobacteriaceae in U.S. medical centers: molecular evaluation from the MYSTIC Program (2007). Microb Drug Res 2008; 14: 211-6.
9. Pitout JD, Laupland KB. Extended-spectrum ß-lactamase-producing Enterobacteriaceae: an emerging public-health concern. Lancet Infect Dis 2008; 8: 159-66.
10. Clinical and Laboratory Standards Institute (CLSI), Performance standards for antimicrobial susceptibility testing; Twenty-first in-formational supplement, document M100-S21. Clinical Laboratory Standards Institute, Wayne, PA 2011.
11. Zhanel GG, Hisanaga T L, Laing N M, et al. Antibiotic resistance in Escherichia coli outpatient urinary isolates: final results from the North American Urinary Tract Infection Collaborative Alliance (NAUTICA). Int J Antimicrob Agents 2006; 27, 468-75.
12. Lagace-Wiens PR, Nichol KA, Nicolle LE, et al. ESBL genotypes in fluoroquinolone-resistant and fluoroquinolone-susceptible ESBL-producing Escherichia coli urinary isolates in Manitoba. Can J Infect Dis Med Microbiol 2007; 18: 133-7.
13. Mac Aogáin M, Mooij MJ, Adams C, Clair J, O'Gara F. Emergence of extended-spectrum beta-lactamase and fluoroquinolone resis-tance genes among Irish multidrug-resistant isolates. Diagn Micro-biol Infect Dis 2010; 67: 106-9.
14. Karlowsky J A, Hoban DJ, DeCorby MR, Laing NM, Zhanel GG. Fluoroquinolone-resistant urinary isolates of Escherichia coli from outpatients are frequently multidrug resistant: Results from the North American Urinary Tract Infection Collaboratory Alliance-Quinolone Resistance study. Antimicrob Agents Chemother 2006; 50: 2251-4.